Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

AChR+ Ocular Myasthenia and Facial Hemispasm: A Case Report of Unusual Association and Botulinum Toxic Type A Safety and Efficacy

Author(s): Stefano Zoccolella*, Angelo Fabio Gigante and Salvatore Misceo

Volume 18, Issue 4, 2023

Published on: 20 October, 2022

Page: [592 - 595] Pages: 4

DOI: 10.2174/1574886317666220908094404

Price: $65

Abstract

Introduction: Hemifacial spasm represents segmental myoclonus of muscles innervated by the facial nerve, which is usually and successfully treated with botulinum toxin. Botulinum toxin (BTX) acts as an acetylcholine release inhibitor at presynaptic cholinergic junctions and therefore is considered contraindicated (or administrable with caution) in patients with neuromuscular disorders like Myasthenia Gravis (MG). Moreover, to date, the association of hemifacial spasm and ocular MG is extremely rare and only a few cases have been described.

Case Presentation: We report the case of a 73 years old man with a 3-year history of ocular MG who developed a left hemifacial spasm. The patient underwent hemispasm, treatment with BTX type A (abobotulinum toxin-A, total dose of 50 IU) that resulted in safe and successful 6 months re-evaluation.

Conclusion: Our results suggest that in selected cases with concomitant MG and conditions characterized by orbicularis oculi spasms or hemispasm, BTX therapy may not be contraindicated and could be given at longer intervals due to prolonged effects.

Keywords: Ocular, myastenia gravis, hemifacial spasm, botulinum, toxin, orbiculararis.

« Previous Next »
[1]
Evoli A, Iorio R. Controversies in ocular myasthenia gravis. Front Neurol 2020; 11: 605902.
[http://dx.doi.org/10.3389/fneur.2020.605902] [PMID: 33329368]
[2]
Roberts ME, Steiger MJ, Hart IK. Presentation of myasthenia gravis mimicking blepharospasm. Neurology 2002; 58(1): 150-1.
[http://dx.doi.org/10.1212/WNL.58.1.150-a] [PMID: 11781428]
[3]
Kurlan R, Jankovic J, Rubin A, Patten B, Griggs R, Shoulson I. Coexistent Meige’s syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue? Arch Neurol 1987; 44(10): 1057-60.
[http://dx.doi.org/10.1001/archneur.1987.00520220055017] [PMID: 3632379]
[4]
Jankovic J, Patten BM. Blepharospasm and autoimmune diseases. Mov Disord 1987; 2(3): 159-63.
[http://dx.doi.org/10.1002/mds.870020303] [PMID: 3509774]
[5]
Hara K, Matsuda A, Kitsukawa Y, Tanaka K, Nishizawa M, Tagawa A. Botulinum toxin treatment for blepharospasm associated with myasthenia gravis. Mov Disord 2007; 22(9): 1363-4.
[http://dx.doi.org/10.1002/mds.21558] [PMID: 17486596]
[6]
Elavarasi A, Goyal V. Botulinum neurotoxin in the treatment of hemifacial spasm associated with myasthenia gravis. Toxicon 2021; 190: 1-2.
[http://dx.doi.org/10.1016/j.toxicon.2020.11.011] [PMID: 33253699]
[7]
Tsuda H, Kamei S, Mizutani T, Saito N, Ishikawa H, Omori K. Blepharospasm in a patient with thymoma and positive anti-acetylcholine receptor antibody. Rinsho Shinkeigaku 2003; 43(8): 500-2.
[PMID: 14658404]
[8]
Tang M, Li W, Liu P, He F, Ji F, Meng F. Blepharospasm with elevated anti-acetylcholine receptor antibody titer. Arq Neuropsiquiatr 2018; 76(8): 522-6.
[http://dx.doi.org/10.1590/0004-282x20180076] [PMID: 30231125]
[9]
Voon YC, Yahya WNNW, Hasan S, Ibrahim NM. Pyridostigmine-induced dystonic blepharospasm in a patient with ocular myasthenia gravis. Mov Disord 2010; 25(9): 1299-300.
[http://dx.doi.org/10.1002/mds.22931] [PMID: 20629121]
[10]
Tarsy D, Bhattacharyya N, Borodic G. Myasthenia gravis after botulinum toxin a for Meige syndrome. Mov Disord 2000; 15(4): 736-8.
[http://dx.doi.org/10.1002/1531-8257(200007)15:4<736::AID-MDS1023>3.0.CO;2-9] [PMID: 10928589]
[11]
Emmerson J. Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis. Mov Disord 1994; 9(3): 367.
[http://dx.doi.org/10.1002/mds.870090319] [PMID: 8041381]
[12]
Fasano A, Bentivoglio AR, Ialongo T, Soleti F, Evoli A. Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology 2005; 64(12): 2155-6.
[http://dx.doi.org/10.1212/01.WNL.0000165997.77985.32] [PMID: 15985599]
[13]
Gonçalves MRR, Barbosa ER, Zambon AA, Marchiori P. Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis. Arq Neuropsiquiatr 1999; 57(3A): 683-5.
[http://dx.doi.org/10.1590/S0004-282X1999000400024] [PMID: 10667297]
[14]
Funakawa I, Yasuda T, Katoh H, Hara K, Terao A. A case of bilateral blepharospasm responsive to edrophonium. Rinsho Shinkeigaku 1992; 32(5): 527-31.
[PMID: 1458732]
[15]
Tambasco N, Filidei M, Nigro P, Parnetti L, Simoni S. Botulinum toxin for the treatment of hemifacial spasm: An update on clinical studies. Toxins 2021; 13(12): 881.
[http://dx.doi.org/10.3390/toxins13120881] [PMID: 34941718]
[16]
Berardelli A, Abbruzzese G, Bertolasi L, et al. Guidelines for the therapeutic use of botulinum toxin in movement disorders. Ital J Neurol Sci 1997; 18(5): 261-9.
[http://dx.doi.org/10.1007/BF02083302] [PMID: 9412849]
[17]
Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004; 75(7): 951-7.
[http://dx.doi.org/10.1136/jnnp.2003.034702] [PMID: 15201348]
[18]
Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999; 52(7): 1487-9.
[http://dx.doi.org/10.1212/WNL.52.7.1487] [PMID: 10227640]
[19]
Highlights of prescribing information. BOTOX® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. Available from: https://www.rxabbvie.com/pdf/botox_pi.pdf (Accessed on: July 14, 2020).

Rights & Permissions Print Cite
Article Metrics
33
1
© 2024 Bentham Science Publishers | Privacy Policy